TR200401903T4 - Raf kınaz tesir önleyici olarak imidazol-2-karboksamid türevleri. - Google Patents

Raf kınaz tesir önleyici olarak imidazol-2-karboksamid türevleri.

Info

Publication number: TR200401903T4
Authority: TR; Turkey
Prior art keywords: sub; sup; alkyl; hydrogen; optionally substituted
Prior art date: 2000-03-06

Application number

TR2004/01903T

Other languages

English (en)

Turkish (tr)

Inventor

Gaiba Alessandra

Kenneth Takle Andrew

Matthew Wilson David

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-06

Filing date

2001-03-02

Publication date

2004-09-21

2001-03-02 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2004-09-21 Publication of TR200401903T4 publication Critical patent/TR200401903T4/xx

Links

NMIZONYLXCOHEF-UHFFFAOYSA-N 1h-imidazole-2-carboxamide Chemical class NC(=O)C1=NC=CN1 NMIZONYLXCOHEF-UHFFFAOYSA-N 0.000 title 1
229940043355 kinase inhibitor Drugs 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 10
229910052739 hydrogen Inorganic materials 0.000 abstract 6
239000001257 hydrogen Substances 0.000 abstract 6
125000003118 aryl group Chemical group 0.000 abstract 3
125000001072 heteroaryl group Chemical group 0.000 abstract 3
150000002431 hydrogen Chemical class 0.000 abstract 3
125000000753 cycloalkyl group Chemical group 0.000 abstract 2
125000000623 heterocyclic group Chemical group 0.000 abstract 2
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
125000002619 bicyclic group Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
125000002950 monocyclic group Chemical group 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
102000009929 raf Kinases Human genes 0.000 abstract 1
108010077182 raf Kinases Proteins 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

TR2004/01903T 2000-03-06 2001-03-02 Raf kınaz tesir önleyici olarak imidazol-2-karboksamid türevleri. TR200401903T4 (tr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0005357.9A GB0005357D0 (en)	2000-03-06	2000-03-06	Compounds

Publications (1)

Publication Number	Publication Date
TR200401903T4 true TR200401903T4 (tr)	2004-09-21

Family

ID=9887051

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TR2004/01903T TR200401903T4 (tr)	2000-03-06	2001-03-02	Raf kınaz tesir önleyici olarak imidazol-2-karboksamid türevleri.

Country Status (12)

Country	Link
US (1)	US6987119B2 (fr)
EP (1)	EP1261602B1 (fr)
JP (1)	JP2003525937A (fr)
AT (1)	ATE266021T1 (fr)
AU (1)	AU2001235844A1 (fr)
DE (1)	DE60103133T2 (fr)
DK (1)	DK1261602T3 (fr)
ES (1)	ES2217118T3 (fr)
GB (1)	GB0005357D0 (fr)
PT (1)	PT1261602E (fr)
TR (1)	TR200401903T4 (fr)
WO (1)	WO2001066540A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1158985B1 (fr)	1999-01-13	2011-12-28	Bayer HealthCare LLC	DIPHENYLE UREES A SUBSTITUTION OMEGA-CARBOXY ARYLE EN TANT QU'INHIBITEURS DE LA KINASE p38
AU1529901A (en) *	1999-11-22	2001-06-04	Smithkline Beecham Plc	Compounds
ATE266022T1 (de) *	2000-03-06	2004-05-15	Smithkline Beecham Plc	Imidazol derivate als raf kinase inhibitoren
GB0112348D0 (en) *	2001-05-19	2001-07-11	Smithkline Beecham Plc	Compounds
GB0121494D0 (en)	2001-09-05	2001-10-24	Smithkline Beecham Plc	Compounds
US20040192689A1 (en) *	2001-09-05	2004-09-30	Dean David Kenneth	Heterocycle-carboxamide derivatives as raf kinase inhibitors
WO2003022832A1 (fr) *	2001-09-05	2003-03-20	Smithkline Beecham P.L.C.	Pyridylfurans et pyrroles inhibiteurs de la kinase raf
GB0121488D0 (en) *	2001-09-05	2001-10-24	Smithkline Beecham Plc	Compounds
SI1478358T1 (sl)	2002-02-11	2013-09-30	Bayer Healthcare Llc	Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
AR038966A1 (es) *	2002-03-18	2005-02-02	Solvay Pharm Bv	Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
WO2004019873A2 (fr)	2002-08-29	2004-03-11	Scios Inc.	Methode pour favoriser l'osteogenese
EP1636585B2 (fr)	2003-05-20	2012-06-13	Bayer HealthCare LLC	Diaryl-urees presentant une activite d'inhibition des kinases
EP1663978B1 (fr)	2003-07-23	2007-11-28	Bayer Pharmaceuticals Corporation	Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
WO2005030091A2 (fr)	2003-09-25	2005-04-07	Scios Inc.	Stents et protheses intra-luminales contenant des inhibiteurs de kinase map
US20050282909A1 (en) *	2003-11-14	2005-12-22	Diks Sander H	Guanylhydrazones in methods of treatment or diagnosis as modulators of signal transduction
CA2577275A1 (fr) *	2004-08-31	2006-03-09	Astrazeneca Ab	Derives de quinazolinone et utilisation de ces derives en tant qu'inhibiteurs du b-raf
MX2007002433A (es) *	2004-09-01	2007-05-04	Astrazeneca Ab	Derivados de quinazolinona y su uso como inhibidores de b-raf.
EP1676574A3 (fr)	2004-12-30	2006-07-26	Johnson & Johnson Vision Care, Inc.	Procédé favorisant la survie des tissus ou cellules griffées
AU2006304897B2 (en) *	2005-10-18	2012-07-12	Janssen Pharmaceutica N.V.	Method of inhibiting FLT3 kinase
WO2007124319A1 (fr)	2006-04-20	2007-11-01	Janssen Pharmaceutica N.V.	Inhibiteurs de la c-fms kinase
US8697716B2 (en)	2006-04-20	2014-04-15	Janssen Pharmaceutica Nv	Method of inhibiting C-KIT kinase
CL2008001626A1 (es)	2007-06-05	2009-06-05	Takeda Pharmaceuticals Co	Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
WO2009012283A1 (fr)	2007-07-17	2009-01-22	Plexxikon Inc.	Composés et procédés pour la modulation des kinases et leurs indications
EP2181987B9 (fr)	2007-08-23	2014-09-03	Takeda Pharmaceutical Company Limited	2-Carbonylaminobenzothiazoles et leur utilisation dans la prévention ou le traitement du cancer
JP5350247B2 (ja)	2007-08-29	2013-11-27	武田薬品工業株式会社	複素環化合物およびその用途
US8865732B2 (en)	2008-03-21	2014-10-21	Novartis Ag	Heterocyclic compounds and uses thereof
WO2009115572A2 (fr) *	2008-03-21	2009-09-24	Novartis Ag	Nouveaux composés hétérocycliques et leurs utilisations
US8697874B2 (en)	2008-12-01	2014-04-15	Takeda Pharmaceutical Company Limited	Heterocyclic compound and use thereof
JO3101B1 (ar)	2008-12-02	2017-09-20	Takeda Pharmaceuticals Co	مشتقات بنزوثيازول كعوامل مضادة للسرطان
KR20140011780A (ko)	2012-07-19	2014-01-29	한미약품 주식회사	단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체
US9242969B2 (en)	2013-03-14	2016-01-26	Novartis Ag	Biaryl amide compounds as kinase inhibitors
US9629851B2 (en)	2013-09-20	2017-04-25	Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis	ROCK in combination with MAPK pathway
WO2015041534A1 (fr)	2013-09-20	2015-03-26	Stichting Het Nederlands Kanker Instituut	P90rsk en combinaison avec raf/erk/mek
WO2015156674A2 (fr)	2014-04-10	2015-10-15	Stichting Het Nederlands Kanker Instituut	Méthode de traitement du cancer
WO2015178770A1 (fr)	2014-05-19	2015-11-26	Stichting Het Nederlands Kanker Instituut	Compositions pour le traitement du cancer
UY36294A (es)	2014-09-12	2016-04-29	Novartis Ag	Compuestos y composiciones como inhibidores de quinasa
AU2017329090B9 (en)	2016-09-19	2019-09-05	Novartis Ag	Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
CA3057969A1 (fr)	2017-05-02	2018-11-08	Novartis Ag	Polytherapie
EP3969449B1 (fr)	2019-05-13	2025-02-12	Novartis AG	Nouvelles formes cristallines de n-(3-(2-(2-hydroxyéthoxy)-6-morpholinopyridin-4-yl)-4-méthylphényl)-2(trifluorométhyl)isonicotinamide servant d'inhibiteurs de raf pour le traitement du cancer
WO2026041859A1 (fr) *	2024-08-19	2026-02-26	Oxford University Innovation Limited	Activateurs de pak1 et/ou pak2 et leur utilisation dans la prévention et/ou le traitement de maladies ou d'affections

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GR75287B (fr)	1980-07-25	1984-07-13	Ciba Geigy Ag
US5236917A (en)	1989-05-04	1993-08-17	Sterling Winthrop Inc.	Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5620999A (en)	1994-07-28	1997-04-15	Weier; Richard M.	Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5514505A (en)	1995-05-15	1996-05-07	Xerox Corporation	Method for obtaining improved image contrast in migration imaging members
EP0833664A1 (fr)	1995-06-12	1998-04-08	G.D. SEARLE & CO.	Traitement d'inflammations par une combinaison d'un inhibiteur de la cyclooxygenase-2 et d'un antagoniste du recepteur de leukotriene b 4?
US5717100A (en)	1995-10-06	1998-02-10	Merck & Co., Inc.	Substituted imidazoles having anti-cancer and cytokine inhibitory activity
KR19990064117A (ko)	1995-10-06	1999-07-26	폴락 돈나 엘.	항암 활성과 사이토킨 억제 활성을 갖는 치환된 이미다졸
GB2306108A (en) *	1995-10-13	1997-04-30	Merck & Co Inc	Treatment of Raf-mediated cancers with imidazole derivatives
CA2250232A1 (fr)	1996-04-03	1997-10-09	Allen I. Oliff	Methode de traitement du cancer
ES2239357T3 (es)	1996-06-10	2005-09-16	MERCK & CO., INC.	Imidazoles sustituidos que tienen actividad inhibidora de citoquinas.
DE69729946T2 (de)	1996-10-15	2005-01-20	G.D. Searle Llc	Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia
AU8757098A (en)	1997-06-30	1999-02-10	Ortho-Mcneil Pharmaceutical, Inc.	2-substituted imidazoles useful in the treatment of inflammatory diseases
US6436966B1 (en)	1997-10-27	2002-08-20	Takeda Chemical Ind., Ltd.	Adenosine A3 receptor antagonists
CN1213022C (zh) *	1997-12-22	2005-08-03	拜尔有限公司	用对称和不对称的取代二苯脲抑制raf激酶
JP2002516322A (ja)	1998-05-22	2002-06-04	スミスクライン・ビーチャム・コーポレイション	新規２−アルキル置換イミダゾール化合物
AU1529901A (en)	1999-11-22	2001-06-04	Smithkline Beecham Plc	Compounds
ATE365730T1 (de)	2000-11-20	2007-07-15	Smithkline Beecham Corp	Neuartige verbindungen

2000
- 2000-03-06 GB GBGB0005357.9A patent/GB0005357D0/en not_active Ceased
2001
- 2001-03-02 US US10/220,675 patent/US6987119B2/en not_active Expired - Fee Related
- 2001-03-02 ES ES01907980T patent/ES2217118T3/es not_active Expired - Lifetime
- 2001-03-02 JP JP2001565356A patent/JP2003525937A/ja not_active Withdrawn
- 2001-03-02 AU AU2001235844A patent/AU2001235844A1/en not_active Abandoned
- 2001-03-02 PT PT01907980T patent/PT1261602E/pt unknown
- 2001-03-02 DE DE60103133T patent/DE60103133T2/de not_active Expired - Fee Related
- 2001-03-02 DK DK01907980T patent/DK1261602T3/da active
- 2001-03-02 AT AT01907980T patent/ATE266021T1/de not_active IP Right Cessation
- 2001-03-02 EP EP01907980A patent/EP1261602B1/fr not_active Expired - Lifetime
- 2001-03-02 TR TR2004/01903T patent/TR200401903T4/xx unknown
- 2001-03-02 WO PCT/GB2001/000916 patent/WO2001066540A1/fr not_active Ceased

Also Published As

Publication number	Publication date
ATE266021T1 (de)	2004-05-15
DE60103133D1 (de)	2004-06-09
US6987119B2 (en)	2006-01-17
EP1261602A1 (fr)	2002-12-04
AU2001235844A1 (en)	2001-09-17
GB0005357D0 (en)	2000-04-26
PT1261602E (pt)	2004-08-31
ES2217118T3 (es)	2004-11-01
WO2001066540A1 (fr)	2001-09-13
DK1261602T3 (da)	2004-08-30
DE60103133T2 (de)	2004-10-14
US20030134837A1 (en)	2003-07-17
JP2003525937A (ja)	2003-09-02
EP1261602B1 (fr)	2004-05-06

Publication	Publication Date	Title
TR200401903T4 (tr)	2004-09-21	Raf kınaz tesir önleyici olarak imidazol-2-karboksamid türevleri.
DE60103136D1 (de)	2004-06-09	Imidazol derivate als raf kinase inhibitoren
EP1724262A4 (fr)	2009-10-21	Derive de 1-(2h)-isoquinolone
EA200602060A1 (ru)	2007-04-27	Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
RU2007110629A (ru)	2008-10-27	Ингибиторы днк-пк
EE200200148A (et)	2003-04-15	Kinasoliini derivaadid, nende valmistamise meetodning kasutamine
SE0202463D0 (sv)	2002-08-14	Novel compounds
NO20082101L (no)	2008-08-15	Pyrido-, pyrazo- og pyrimido-pyrimidinderivater som mTor inhibitorer
MXPA02011974A (es)	2004-09-06	Derivados de quinazolina sustituidos y su uso como inhibidores.
TNSN03110A1 (fr)	2005-12-23	Azaindoles.
NO20060145L (no)	2006-03-07	Substituerte indazolyl (indolyl) maleimidderivater som kinase inhibitorer
AR029216A1 (es)	2003-06-18	Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
BR0315405A (pt)	2005-08-09	Compostos inibidores da integrase tricìclica pré-organizados
HRP20040429B1 (hr)	2007-10-31	Derivati sulfonamida, njihova priprema i upotrebakao lijekova
EA201170196A1 (ru)	2011-12-30	Производные бензазепинов и их применение в качестве h3 гистаминовых антагонистов
HUP0400246A2 (hu)	2004-08-30	1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
SE0400284D0 (sv)	2004-02-10	Novel compounds
ATE403653T1 (de)	2008-08-15	Pyridin-substituierte furanderivate als raf- kinase inhibitoren
DE602006011752D1 (de)	2010-03-04	Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
AR047531A1 (es)	2006-01-25	Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
MX2025003324A (es)	2025-05-02	Inhibidores de sik heterociclicos
EA200701780A1 (ru)	2008-02-28	Противоопухолевое средство
UA74341C2 (uk)	2005-12-15	Похідні борелідину, які інгібують ангіогенез
EA200001009A1 (ru)	2001-02-26	Производные пиридина, ингибирующие фосфодиэстеразу iv
PT1572198E (pt)	2006-08-31	Novos compostos farmaceuticos com actividade de receptor alfa2.